MIMEDX GROUP INC - CO

MIMEDX Appoints Matt Notarianni as Head of Investor Relations

04 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

MIMEDX Announces Launch of AXIOFILL™

20 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

MIMEDX Announces Launch of AMNIOEFFECT™

19 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

12 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

MIMEDX Announces Leadership Transition

06 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin

26 Aug 2022 09:00:00 By Nasdaq GlobeNewswire

MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

04 Aug 2022 16:08:43 By Nasdaq GlobeNewswire

MIMEDX Announces Second Quarter 2022 Operating and Financial Results

02 Aug 2022 16:07:16 By Nasdaq GlobeNewswire

MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

27 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

20 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

18 Jul 2022 09:35:23 By Nasdaq GlobeNewswire

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

15 Jun 2022 08:30:00 By Nasdaq GlobeNewswire

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

07 Jun 2022 16:05:29 By Nasdaq GlobeNewswire

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

03 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

MIMEDX Addresses Presentation by Prescience Point

02 Jun 2022 08:03:35 By Nasdaq GlobeNewswire

MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders

31 May 2022 16:05:00 By Nasdaq GlobeNewswire

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

31 May 2022 08:00:01 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

25 May 2022 17:26:30 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

20 May 2022 09:00:00 By Nasdaq GlobeNewswire

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

18 May 2022 16:18:33 By Nasdaq GlobeNewswire